Posted by Michael Wonder on 08 Jan 2018
Brexit fears are diverting millions of pounds from vital cancer battle, say drug firms
7 January 2018 - Brexit could see pharmaceutical firms having to contend with more regulations.
Millions of pounds earmarked for the battle against cancer are being diverted by drugs firms towards preparations for a hard Brexit, MPs have been told.
If Britain leaves the EU without a deal in place covering their sector, the pharmaceutical companies will have to reregister and repackage thousands of medicines and conform to a welter of fresh regulations.
